Improving patient access to hepatitis C antiviral medicines in Switzerland: Understanding the financial risks for community pharmacies.
Jérôme BergerAline BourdinFatima PiresClaudine BackesClemence PerraudinOlivier BugnonPublished in: Journal of evaluation in clinical practice (2018)
The scenario analysis clarifies the causes of the possible refusal to deliver HCVm. With the growing number of high-priced medicines, the healthcare systems should have a clear strategy to encourage their delivery by community pharmacies by ensuring seamless and collaborative care for patients. The community pharmacists could be accountable to provide such services-if they get the education, training, and remuneration.